SOL-116 a drug candidate with groundbreaking potential

Lipum’s drug candidate SOL-116 is a humanized antibody expected to offer a unique mechanism of action for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA). Our goal is for SOL-116 to alleviate painful symptoms and improve the quality of life for the millions of patients suffering from chronic inflammatory diseases.

Lipum has completed and published the Clinical Study Report (CSR) for its First-in-Human (FIH) Phase I trial evaluating SOL-116. The study investigated single ascending doses (SAD) and multiple doses (MD) of SOL-116 in healthy volunteers, as well as a single dose in patients with mild rheumatoid arthritis (RA), and the findings support further clinical development for potential rheumatoid arthritis therapy. Read more about the study results here »

The Road to Market: A Transparent Look at Biologic Drug Production

This series in six parts explores key aspects of the biologic drug manufacturing journey and aims to provide valuable insights into its complexities — from early process development to commercial production — through the perspectives of both the developer and the CDMO. It offers a transparent discussion on the realities of bringing a biologic to market.